HC Wainwright Has Pessimistic Outlook of OTLK Q2 Earnings

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Stock analysts at HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for shares of Outlook Therapeutics in a research report issued on Tuesday, February 18th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($0.60) per share for the quarter, down from their previous forecast of ($0.58). HC Wainwright currently has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($2.25) per share. HC Wainwright also issued estimates for Outlook Therapeutics’ Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($2.33) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at $0.62 EPS and FY2028 earnings at $2.37 EPS.

Outlook Therapeutics (NASDAQ:OTLK) last issued its earnings results on Friday, February 14th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.04).

A number of other analysts have also issued reports on the company. Guggenheim reissued a “buy” rating and issued a $12.00 target price on shares of Outlook Therapeutics in a research report on Friday, January 17th. Chardan Capital restated a “neutral” rating and issued a $3.00 price objective on shares of Outlook Therapeutics in a research note on Tuesday. Finally, BTIG Research decreased their target price on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 29th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Outlook Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $12.00.

Outlook Therapeutics Stock Performance

OTLK opened at $1.64 on Thursday. Outlook Therapeutics has a one year low of $0.87 and a one year high of $12.85. The stock has a market capitalization of $52.51 million, a PE ratio of -0.22 and a beta of 0.58. The business’s 50 day moving average price is $1.89 and its 200 day moving average price is $4.33.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its holdings in Outlook Therapeutics by 49.2% during the third quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock worth $1,826,000 after purchasing an additional 112,812 shares in the last quarter. State Street Corp increased its stake in shares of Outlook Therapeutics by 10.0% during the 3rd quarter. State Street Corp now owns 232,542 shares of the company’s stock worth $1,242,000 after purchasing an additional 21,201 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Outlook Therapeutics by 1,329.6% during the 4th quarter. Rhumbline Advisers now owns 188,050 shares of the company’s stock worth $355,000 after purchasing an additional 174,896 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Outlook Therapeutics during the 4th quarter worth approximately $246,000. Finally, Scotia Capital Inc. boosted its position in Outlook Therapeutics by 124.4% during the fourth quarter. Scotia Capital Inc. now owns 73,989 shares of the company’s stock worth $140,000 after acquiring an additional 41,023 shares during the last quarter. 11.20% of the stock is owned by hedge funds and other institutional investors.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.